We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Raul Mitrani

Raul D Mitrani MD, FACC, FHRS

Director of Clinical Cardiac Electrophysiology, and Director of the Cardiac Electrophysiology Laboratory at University of Miami, Miller School of Medicine, Miami, FL

Dr Raul Mitrani is Director of Clinical Cardiac Electrophysiology, and Director of the Cardiac Electrophysiology Laboratory at University of Miami, Miller School of Medicine. As an Academic Cardiac Electrophysiologist, Dr Mitrani treats patients with simple and complex cardiac arrhythmias including atrial fibrillation, ventricular tachycardia, supraventricular tachycardia and syncope. He performs the full gamut of cardiac ablation procedures as well as cardiac electrical device implants.

In addition to his clinical responsibilities, Dr Mitrani is actively involved in research and teaching. He has authored or coauthored numerous papers on diverse topics including the role of cardiac stem cells in cardiac arrhythmias, optimal blood pressure control in patients with atrial fibrillation, and others. Recently, he has co-authored chapters and review articles on the topic of Sudden Cardiac Death. He is currently involved in preclinical studies on the effects of mesenchymal stem cells in a post –infarct swine model. He is involved in various NIH-sponsored trials including the CONCERT-HF Trial, a study of Combination of Mesenchymal and C-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure (CONCERT-HF; NCT02501811). He also is involved in studies examining the effects of Mesenchymal Stem Cells in patients with nonischemic cardiomyopathy (POSEIDON-DCM -NCT01392625) and ischemic cardiomyopathy (TRIDENT -NCT02013674). He participates in NIH sponsored multicenter trials such as the CABANA Trial, a study to compare catheter ablation versus pharmacologic therapy in patients with atrial fibrillation.

Disclosures

He is currently involved in preclinical studies on the effects of mesenchymal stem cells in a post –infarct swine model. He is involved in various NIH-sponsored trials including the CONCERT-HF Trial, a study of Combination of Mesenchymal and C-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure (CONCERT-HF; NCT02501811). He also is involved in studies examining the effects of Mesenchymal Stem Cells in patients with nonischemic cardiomyopathy (POSEIDON-DCM -NCT01392625) and ischemic cardiomyopathy (TRIDENT -NCT02013674). He participates in NIH sponsored multicenter trials such as the CABANA Trial, a study to compare catheter ablation versus pharmacologic therapy in patients with atrial fibrillation.